<DOC>
	<DOCNO>NCT00620100</DOCNO>
	<brief_summary>To determine Objective Response Rate 4 cycle docetaxel + anthracycline ( epirubicin doxorubicine ) follow 4 cycle docetaxel single agent . To determine Time Tumor Progression ( TTP ) , Response Duration , Overall Survival . To confirm safety profile</brief_summary>
	<brief_title>To Determine Objective Response Rate 4 Cycles Docetaxel + Anthracycline ( Epirubicin Doxorubicine ) Followed 4 Cycles Docetaxel Single Agent</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Female patient histologically cytologically document breast adenocarcinoma 2 . First local metastatic relapse 3 . Patients must receive prior neoadjuvant adjuvant Taxotere®based chemotherapy regimen , provide chemotherapy complete &gt; = 12 month prior enrollment date 4 . Prior hormone immune therapy allow . Antitumoral adjuvant hormone therapy may continue study period , provide start &gt; 12 month prior study enrollment 5 . Her2/neu negative tumor demonstrate immunohistochemistry ( IHC 0 1+ ) fluorescence situ hybridation ( FISH ) . A patient tumor assess 2+ IHC enrol tumor negative FISH . 6 . ECOG performance status 0 2 7 . Normal cardiac function confirm LVEF shorten fraction ( MUGA scan echocardiography , respectively , within normal limit institution ) assess within 3 month prior study entry . An ECG must obtain within 4 week prior study entry must demonstrate clinically significant abnormality . 8 . Patients require least one measurable lesion accord RECIST guideline 9 . Adequate organ function define : 1 . Hematology : Neutrophils &gt; = 2.0 109/L , Platelets &gt; = 100 109/L , Hemoglobin &gt; = 10 g/dL 2 . Hepatic function : Total bilirubin within normal limit , AST ( SGOT ) ALT ( SGPT ) &lt; = 1.5 UNL , alkaline phosphatase &lt; = 2.5 UNL ( unless accompany extensive bone metastasis ) 10 . Negative pregnancy test ( urine serum ) within 7 day prior registration woman childbearing potential 11 . Written inform consent prior begin specific protocol procedure must obtain document accord local regulatory requirement Exclusion Criteria 1 . Prior therapy advance recurrent disease 2 . Previous cumulative exposure epirubicin &gt; 600 mg/m² doxorubicin &gt; 300 mg/m² 3 . Previous radiation therapy involve 25 % bone marrow ; incomplete recovery toxicity radiation therapy 4 . Symptomatic brain metastasis clinically diagnose leptomeningeal metastasis 5 . Isolated unmeasurable bone lesion , serous pleural effusion pulmonary lymphangiitis ( i.e. , unmeasurable disease accord RECIST guideline ) 6 . Preexisting motor sensory neurologic toxicity severity &gt; = grade 2 accord NCICTC AE criterion version 3.0 7 . Pregnant lactate woman woman childbearing potential use adequate contraception 8 . Other serious illness medical condition , include : 1 . Congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrhythmias 2 . History significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would hamper understand give informed consent . 3 . Active uncontrolled infection 4 . Active peptic ulcer , uncontrolled diabetes mellitus 9 . Past current history neoplasm breast carcinoma , except : 1 . Curatively treated nonmelanoma skin cancer . 2. situ carcinoma cervix . 3 . Other cancer curatively treat evidence disease least 10 year 10 . Chronic treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose ( &lt; = 20 mg methylprednisolone per day equivalent ) 11 . Definite contraindication use corticosteroid 12 . Likelihood require treatment study period drug permit clinical study protocol ( see Section 6.2 ) 13 . Concurrent treatment investigational drug . Active treatment part another clinical therapeutic trial within 30 day prior study entry 14 . Concurrent treatment anticancer therapy , except adjuvant hormone therapy start &gt; = 12 month prior study enrollment . Bisphosphonates management bone metastases osteoporosis/osteopenia allow 15 . History hypersensitivity docetaxel ( drug formulate polysorbate 80 ) , epirubicin doxorubicin 16 . Mental condition render subject unable understand nature , scope , possible consequence study 17 . Subject unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>